Long‐term outcome in Caucasian patients with chronic hepatitis B virus infection after HBsAg seroclearance

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 35, Iss. 1, 2015-01 ,pp. : 140-147

John Wiley & Sons Inc

Access to resources Recommend Favorite

IFNL4 rs368234815 and rs117648444 variants predict off‐treatment HBsAg seroclearance in IFN‐treated HBeAg‐negative chronic hepatitis B patients

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 38, Iss. 3, 2018-03 ,pp. : 417-423

John Wiley & Sons Inc

Access to resources Recommend Favorite

Analysis of hepatitis B surface antigen (HBsAg) using high‐sensitivity HBsAg assays in hepatitis B virus carriers in whom HBsAg seroclearance was confirmed by conventional assays

By  

HEPATOLOGY RESEARCH, Vol. 48, Iss. 3, 2018-02 ,pp. : E263-E274

John Wiley & Sons Inc

Access to resources Recommend Favorite

P064: Hepatitis B surface Antigen (HBsAg) levels in chronic hepatitis B patients ‐ a comparison between patients of different ages and their hepatitisBeAntigen (HBeAg) seroconversion status in a prospective cohort

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 22, Iss. S2, 2015-06 ,pp. : 52-52

John Wiley & Sons Inc

Access to resources Recommend Favorite

HBsAg loss is not an ideal indicator for discontinuing treatment of HBeAg-negative chronic hepatitis B: a case report

By Dong Pei-ling   Zhang Xin   Zhao Wen-min   Ding Hui-guo  

Journal of Infection and Chemotherapy, Vol. 19, Iss. 6, 2013-12 ,pp. : 1188-1192

Springer Publishing Company

Access to resources Recommend Favorite